AstraZeneca 관리

관리 기준 확인 3/4

AstraZeneca CEO는 Pascal Soriot, Oct2012 에 임명되었습니다 의 임기는 12.08 년입니다. 총 연간 보상은 $ 21.48M, 8.5% 로 구성됩니다. 8.5% 급여 및 91.5% 보너스(회사 주식 및 옵션 포함). 는 ARS 29.18B 가치에 해당하는 회사 주식의 0.014% 직접 소유합니다. 29.18B. 경영진과 이사회의 평균 재임 기간은 각각 9.4 년과 7 년입니다.

주요 정보

Pascal Soriot

최고 경영자

US$21.5m

총 보상

CEO 급여 비율	8.5%
CEO 임기	12.1yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	9.4yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

업데이트 없음

Recent updates

CEO 보상 분석

Pascal Soriot 의 보수는 AstraZeneca 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$21m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$2m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$3b
Mar 31 2018	n/a	n/a	US$3b
Dec 31 2017	US$14m	US$2m	US$3b

보상 대 시장: Pascal 의 총 보상 ($USD 21.48M )은 AR 시장( $USD 5.75M ).

보상과 수익: Pascal 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Pascal Soriot (65 yo)

12.1yrs

테뉴어

US$21,484,390

보상

Mr. Pascal Soriot, M.B.A., D.V.M., has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. He served as Director at Acerta Pharma B.V. He had been Independent...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% ARS 29.2b
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% ARS 10.9b
Pam Cheng	EVP of Global opt. & IT	9.4yrs	데이터 없음	데이터 없음
Andrew Barnett	Head of Investor Relations	no data	데이터 없음	데이터 없음
Jeffrey Pott	CHRO, Chief Compliance Officer	15.8yrs	데이터 없음	데이터 없음
Gonzalo Vina	Head of Global Media Relations	no data	데이터 없음	데이터 없음
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	11.8yrs	데이터 없음	데이터 없음
Susan Galbraith	Executive Vice President of Oncology Research & Development	no data	데이터 없음	데이터 없음
Leon Wang	Executive VP of International & China President	10.8yrs	데이터 없음	데이터 없음
Iskra Reic	Executive Vice-President of Vaccines & Immune Therapies	7.6yrs	데이터 없음	데이터 없음
David Fredrickson	Executive Vice-President of Oncology Business Unit	7.1yrs	데이터 없음	데이터 없음
Ruth March	Senior VP of Precision Medicine - R&D Oncology	5.8yrs	데이터 없음	데이터 없음

9.4yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: AZN 의 관리팀은 노련하고 경험 (평균 재직 기간 9.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% ARS 29.2b
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% ARS 10.9b
Pam Cheng	EVP of Global opt. & IT	no data	데이터 없음	데이터 없음
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	데이터 없음	데이터 없음
Marcus Wallenberg	Non-Executive Director	25.6yrs	US$159.35k	0.0039% ARS 7.9b
Philip John Broadley	Senior Independent Non-Executive Director	7.6yrs	US$254.96k	0.00052% ARS 1.1b
Michel Demare	Independent Chairman	5.2yrs	US$744.49k	0.00065% ARS 1.3b
Deborah DiSanzo Eldracher	Independent Non-Executive Director	6.9yrs	US$152.98k	0.000060% ARS 122.6m
Sherilyn S. McCoy	Independent Non-Executive Director	7.1yrs	US$223.09k	0.00011% ARS 224.8m
Euan Ashley	Independent Non-Executive Director	4.1yrs	US$151.70k	0.000070% ARS 143.0m
Shu Kam Mok	Independent Non-Executive Director	5.8yrs	US$140.23k	0.00013% ARS 265.6m
Nazneen Rahman	Independent Non-Executive Director	7.4yrs	US$203.97k	0.000070% ARS 143.0m

7.0yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: AZN 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

AstraZeneca 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Recent updates

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령